摘要
目的分析曲妥珠单抗对HER2阳性晚期食管癌患者的临床疗效。方法选取2016年12月-2018年12月广东省韶关市第一人民医院收治的28例HER2阳性晚期食管癌患者,随机分两组,均对其进行放射治疗(IMRT),研究组加入曲妥珠单抗联合替吉奥加奥沙利铂进行治疗,观察两组治疗结果。结果观察两组患者近期疗效及远期疗效,近期治疗中,研究组和对照组的RR,DCR分别是78.57%,92.86%和57.14%,78.57%,差异有统计学意义(P<0.05);远期治疗中,研究组和对照组在一、二年的生存率分别78.57%,64.29%和64.29%,50%(P<0.05),三年的生存率分别为42.86%和35.57%(P>0.05);研究组和对照组的PFS分别是23个月和18个月;治疗过程中,研究组的不良反应低于对照组。结论曲妥珠单抗联合替吉奥加奥沙利铂可以提高HER2阳性晚期食管癌患者的RR、DCR且能有效控制不良反应,但未明显提高患者一、二、三年生存率,可用于临床。
Objective To analyze the clinical efficacy of trastuzumab in patients with her2-positive advanced esophageal cancer.Methods Twenty-eight patients with her2-positive advanced esophageal cancer admitted to our hospital from December 2016 to December 2018 were randomly divided into two groups and treated with radiotherapy(IMRT).Trastuzumab combined with tiggioga oxaliplatin was added to the study group to observe the treatment results of the two groups.Results The short-term and long-term efficacy of the two groups were observed.In the short-term treatment,RR and DCR in the study group and the control group were 78.57%,92.86%,57.14%and 78.57%,respectively.The difference was statistically significant(P<0.05).In the long-term treatment,the 1-year and 2-year survival rates of the study group and the control group were 78.57%,64.29%and 64.29%,and 50%,respectively,with statistically significant differences(P<0.05).The 3-year survival rates were 42.86%and 35.57%,respectively(P>0.05).the study group and the control group were 23 and 18 months,respectively.During treatment,the adverse reactions in the study group were lower than those in the control group.Conclusion Trastuzumab combined with tiggioga oxaliplatin could improve RR and DCR in patients with advanced her2-positive esophageal cancer and effectively control adverse reactions,but it did not significantly improve the survival rate of patients at 1,2,and 3 years,which could be used in clinical application.
作者
陈智翔
CHEN Zhixiang(Department of general surgery,the first people's Hospital of Shaoguan City,Shaoguan,Guangdong 512000)
出处
《智慧健康》
2022年第4期123-126,共4页
Smart Healthcare
